Biotech Values

[rfj1862]

>One would think a superior product on both safety and efficacy endpoints woudl capture even more than JAV's numbers, which are based on a 20-35% market share<

In the current environment, even more important is the ability to bolus dose. Pharmacoeconomic analyses indicate about a 50 pound stirling savings associated with bolus dosing over infusion. That's huge, and well worth the extra $7 (or about 3.50 stirling) per vial.